Icahn begins his assault on Forest Labs CEO

Once it became apparent that Carl Icahn had accumulated a significant stake in Forest Labs, the analysts sat back waiting for the other shoe to drop. That happened today, as Icahn targeted Forest CEO Howard Solomon for a long litany of abuses: From trouble with the feds to a "poor" record on earnings. Icahn has made a fortune toppling biopharma CEOs at Biogen Idec and Genzyme. And with close to 7 percent of Forest's shares in his portfolio, it appears that the 83-year-old Solomon is now in for the Icahn treatment. Story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.